Montelukast alleviates neuroinflammation and improves motor functions in the line 61 model of Parkinson's disease: An exploratory study.

ABSTRACT: Parkinson's disease (PD) is a neurodegenerative movement disorder of high global burden. Uncertainties regarding its exact etiology have been hindering the development of curative therapies. As microglia, the brain's immune cells, are suspected to contribute to neurodegeneration by instigating neuroinflammation, existing anti-inflammatory agents could potentially serve as disease-modifying treatments for PD. Here we evaluated the impact of montelukast, a leukotriene receptor antagonist and anti-inflammatory drug, on motor symptoms and neuropathology in an α-synuclein transgenic mouse model (Line 61) for early onset/genetic PD. Two -weeks -old male Line 61 mice and non-transgenic littermates received daily 10 ​mg/kg montelukast or vehicle orally for 10 weeks. Motor functions were assessed t

SUBMITTER: Strempfl K 

PROVIDER: S-EPMC12491803 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature